Bacterial pneumonia
For the main page on pneumonia, click here
For the patient information on pneumonia, click here
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Arooj Naz, M.B.B.S
Overview
Editor(s)-in-Chief: Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Philip Marcus, M.D., M.P.H.[2] Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Bacterial pneumonia is an infection of the lungs by bacteria.
Streptococcus pneumoniae is the most common bacterial cause of pneumonia in all age groups except newborn infants. Streptococcus pneumoniae is a gram-positive bacteria which often lives in the throat of people who do not have pneumonia. Another important gram-positive cause of pneumonia is Staphylococcus aureus.
Gram-negative bacteria are seen less frequently; Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa and Moraxella catarrhalis are the most common. These bacteria often live in the gut and enter the lungs when contents of the gut (such as vomit) are inhaled.
The “atypical” bacteria are Coxiella burnetti, Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila. They are “atypical” because they commonly affect teenagers and young adults, are less severe, and require different antibiotics than typical bacteria such as Streptococcus pneumoniae.
Historical Perspective
Since the 20th century, bacterial pneumonia has been identified as a formidable infectious disease and was largely held responsible for deaths during the Influenza Pandemic of 1918. It was often referred to as “captain of the men of death” during this timeframe. The most common causative bacterial strain, Streptococcus pneumoniae, was first isolated in 1880 by Louis Pasteur and George Sternberg. In general, the disease has varying outcomes. The discovery of modern-day antibiotics have entirely changed how treatment is approached but, before them, blood letting was a common method of treatment as was described by William Osler in his textbook, The Principles and Practice of Medicine, written in 1892.
Pathophysiology
Causative bacteria can be inhaled from the surrounding environment but organisms are also commonly found within the upper respiratory tract of many individuals from where they can be directed towards the alveoli. Once in the bloodstream of the lungs, the immune system triggers a response by mobilizing white blood cells into the affected area. Neutrophils and cytokine help in ridding the body of infectious organisms but also result in systemic symptoms such as fever, chills, and fatigue. If bacteria enters the systemic blood stream, sepsis may ensue and can involve other organs including the brain, kidney, and heart.
Causes
Bacterial pneumonia may be due to a variety of underlying causes. The microorganisms responsible are divided into typical and atypical. Typical bacteria often result in a classic pneumonia whereas atypical bacteria lead to a much milder presentation often referred to as “walking pneumonia“. These patients appear near normal but have extensive findings on chest x-ray. Apart from typical and atypical classifications, bacterial pneumonia can be categorized based on demographics by differentiating into neonates (<4 weeks old), toddlers (2 – 4 years), children (4 weeks – 18 years), adults (18 – 65 years), and the elderly (>65 years). Underlying characteristics may also help determine the specific cause. These include alcoholics, those at risk of aspiration, cystic fibrosis, intravenous drug users, and those that are immunocompromised or at risk of nosocomial pneumonia.
Differential Diagnosis
Symptoms related to pulmonary diseases may overlap and so, it is important to differentiate bacterial causes from other diseases. This can be done with the assistance of laboratory examinations such as chest x-ray findings and throat culture and sensitivity bacterial cultures. Some pulmonary diseases that must be differentiated include bronchitis, bronchiolitis obliterans, empyema, lung abscess and pulmonary carcinomas. Other diseases to be ruled out include bacterial endocarditis, especially in patients with an underlying history of intravenous drug abuse, GERD, and sinusitis.
Epidemiology and Demographics
Pneumonia is a condition seen in the vast majority of regions, but pneumonia related deaths have been disproportionally higher in low and middle income nations, including the sub-Saharan African and South Asian regions. Pneumonia case rates are primarily affected by factors relating to seasonal variations. Studies show that a majority of Streptococcus pneumoniae cases were most prevalent during the winter, whereas far fewer cases presented in the summertime in comparison. Specifications regarding geography are of considerable importance in regards to fungal pneumonia.
Risk Factors
Bacterial pneumonia can affect individuals of any age, gender, or race and has minimal significance in relation to family history. Individuals with underlying immunoglobulin defects have a significantly higher likelihood of infection. Bacterial pneumonia tends to affect men more often than women, and is more common in African Americans compared to Caucasians. Socioeconomic status is an important contributing factors and may explain the increased prevalence rate in low to middle-income nations. Pneumonia may also be affected by the use of medications such as proton pump inhibitors and ACE inhibitors. Immunocompromised patients requiring in-hospital treatment may develop nosocomial pneumonia but this can also present in seemingly healthy patients with prolonged durations of stay. A majority of nosocomial pneumonia will developed within 48 hours but some may present later on. The most common pathogens causing nosocomial pneumonia include Gram-positive cocci (e.g, Staphylococcus aureus, which includes methicillin-resistant S. aureus, and Streptococcus species) and Aerobic gram-negative bacilli (e.g. Pseudomonas Aeruginosa, Escherichia Coli, Klebsiella Pneumoniae, Enterobacter species, Acinetobacter species).
Natural History, Complications and Prognosis
Bacterial pneumonia is often transmitted via oral secretions and undergoes a variety of stages including congestion, hepatization and resolution. Symptoms may vary amongst individuals but commonly include abrupt fever, chills, rigors, and cough. Infectious organisms are commonly transmitted via oral secretions containing droplets and the incubation period is generally short and ranges from 1-3 days. Germs can also be transferred by touching unclean surfaces with hands that may later come in contact with the eyes, nostrils, or mouth allowing bacteria to enter the body. There are a multitude of pulmonary and extra-pulmonary complications that contribute to determining the outcome of recovery. Common complications include acute respiratory distress, pleural effusion, sepsis and shock. Prognosis varies according to age and underlying conditions such as bronchiectasis, abscesses, and neoplasms. The CURB-65 scale takes into account confusion, BUN, respiratory rate, blood pressure, and age. A score of 3 or more requires a prolonged hospital duration and has a higher risk of mortality. This criteria has proven to be a useful tool in predicting the outcome of disease.
History and Symptoms
Detailed information pertaining to a patient’s history may greatly assist in determining the underlying cause of pneumonia. Some common symptoms seen in a majority of patients include cough, fever, and a pleuritic chest pain. Specific signs and symptoms, such as diarrhea, hyponatremia, and anemia may increase the suspiciousness of specific causative organisms. Details pertaining to cough may assist in identifying the underlying cause. It is also important to inquire about risk factors and comorbidities as they can provide important information regarding the bacterial infection.
Physical Examination
Although physical examination may differ amongst patients, many presents with similar findings. Variations may be due to the severity and extent of disease, the causative bacteria, as well as the presence or absence of any complications. Much of the systemic examination may appearently be normal with the exception of some in cases of specific infections. All patients present with significant pulmonary findings and changes in vital signs. With the development of complications such as sepsis, neurological findings such as confusion can also develop.
Laboratory Findings
Patients infected with bacterial pneumonia present with a high leukocyte count as well as elevated inflammatory biomarkers. including ESR and C-RP. Red blood cell and platelet count can also be affected presenting as anemia and thrombocytopenia. Arterial blood gasses will often show changes in pH leading to a respiratory acidosis. Other tests routinely done include electrolyte assessment, renal function tests, pulse oximetry, gram staining and sputum samples. Blood cultures and PCR tests are sensitive tests that can provide a definitive diagnosis and aid in the selection of antibiotics.
Chest X-Ray
Imaging with chest x-rays remains the gold standard of diagnosis when supported with other laboratory findings. Although x-ray findings provide reliable findings, it is recommended that the entire clinical picture along with supporting laboratory findings be taken into consideration before treatment is started. Patterns commonly found on imaging include lobar or focal nonsegmental pneumonia, lobular or multifocal bronchopneumonia, and diffuse or interstitial (atypical) pneumonia. Radiological findings may take 6-12 weeks to clear.
CT Scan
Although CT scans are not a primary modality of testing for bacterial pneumonia, they may be utilized in complex cases where the underlying cause is unknown and or when empiric antibiotic use yields no symptomatic relief in the patient. CT scans may be very informative and assist in differentiating infectious and noninfectious pneumonia. Similar to chest x-rays, CT findings can also be described according to the type of pneumonia including lobar or focal nonsegmental pneumonia, lobular or multifocal bronchopneumonia, and diffuse or interstitial (atypical) pneumonia.
Other Imaging Findings
Bacterial pneumonia is primarily diagnosed with chest x-ray and, in complex cases, CT scans. Other diagnostic tests are available but are frequently not utilized compared to the aforementioned two modalities. These include ultrasonography, chest MRI, and biopsy of the affected lung. Ultrasonography can help identify the pleural fluid including its amount, viscosity and loculations as well as pulmonary septations. Lung biopsy is a reliable but invasive method of diagnosing pneumonia so they are often reserved for cases in which the underlying cause can not be identified. Bronchopsy may also be utilized in diagnosing pneumonia, especially in non-immunocompromised and mechanically ventilated patients.
Other Diagnostic Studies
Diagnostic studies apart from routine laboratory test helpful in diagnosing bacterial pneumonia include bronchoalveolar lavage and urine antigen, which is helpful in the diagnosis of legionella. Bronchoalveolar lavage provides accurate results but obtaining a sample may present some difficulties therefore it is done in patients who are intubated and can provide a sample therefore, it is usually reserved for patients that are on mechanical ventilation.
Medical Treatment
Antibiotics are the treatment of choice for bacterial pneumonia. The antibiotic choice depends on the nature of the pneumonia, the microorganisms most commonly causing pneumonia in the geographical region, and the immune status and underlying health of the individual. In the United Kingdom, amoxicillin is used as first-line therapy in the vast majority of patients who acquire pneumonia in the community, sometimes with added clarithromycin. In North America, where the “atypical” forms of community-acquired pneumonia are becoming more common, clarithromycin, azithromycin, or fluoroquinolones as single therapy, have displaced the amoxicillin as first-line therapy. Local patterns of antibiotic-resistance should always be considered when initiating pharmacotherapy. In hospitalized individuals or those with immune deficiencies, local guidelines determine the selection of antibiotics. These antibiotics are typically given through an intravenous line.
Primary Prevention
The goal of Primary prevention is to prevent the occurrence of an illness or a disease before it ever occurs. In the case of bacterial pneumonia, primary prevention can be achieved by the administration of vaccination as well as attempting to control underlying comorbidities that may predispose an individual to pneumonia. Pneumococcus Vaccines include the PCV13 (Conjugate vaccine) and the PPSV23 (Polysaccharide vaccine). The PCV13 vaccine is indicated in infants and childhood routine vaccines (children younger than 2 years) as well as all adults aged 65 years or older whereas the PPSV23 vaccine is recommended for all adults over the age of 65 as well as adults aged 19-64 with certain medical conditions including chronic heart, lung, or liver diseases, diabetes, smokers and alcoholics. The killed intramuscular influenza vaccine should be given annually. Strict blood glucose and blood pressure control can help in preventing disease prevalence. When certain conditions are present, such as in children that have asplenia, it may also be helpful to treat with prophylactic antibiotics. Educating the public as well as identifying those most susceptible to infection can help reduce the risk of pneumonia.
Secondary Prevention
Secondary prevention occurs once the disease has occurred and aims to prevent progression and complication development. Protective measurements include controlling the tidal volume, plateau pressure, PEEP, and FiO2. Measures taken to reduce the risk of aspiration such as elevation of the head end of bed and maintaining oral hygiene also help preventing aspiration pneumonia. Common complications that can develop due to bacterial pneumonia include acute respiratory distress, pleural effusion, heart failure due to pneumonia, sepsis and septic shock.
Cost-effectiveness of Therapy
The use of antibiotics and corticosteroids had proven to be a cost-effective strategy in treating community-acquired pneumonia. Together, they resulted in savings of $142,795 per death averted. In severe cases of community-acquired pneumonia, the combination of antibiotics and corticosteroids yielded savings of $70,587 and had an 82.6% chance of being cost-effective. The cost effectiveness of ceftolozane/tazobactam versus meropenem was also analyzed and resulted in significant savings in early treatment.
Future or Investigational Therapies
Due to increasing antibiotic resistance and emerging organisms, it is important that the approaches to diagnosing pneumonia continue to advance. Currently, the host factors predisposing one to pneumonia are being studied in detail. Host directed therapeutic approaches against pneumonia infection may prove to be very advantageous. These include host susceptibility, host response to pneumonia and host consequences. Host susceptibility takes into consideration the age, genetic factors, exposures, acute and chronic diseases. The genetic factors being focused on right now include variants in the NGR1, PAK6, MATN1 and FER genes. The host response take into account Immune resistance and repair mechanisms. Host consequences refer to the development of complications and exacerbation of existing chronic conditions.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Since the 20th century, bacterial pneumonia has been identified as a formidable infectious disease and was largely held responsible for deaths during the Influenza Pandemic of 1918. It was often referred to as “captain of the men of death” during this timeframe. The most common causative bacterial strain, Streptococcus pneumoniae, was first isolated in 1880 by Louis Pasteur and George Sternberg. In general, the disease has varying outcomes. The discovery of modern-day antibiotics have entirely changed how treatment is approached but, before then, blood letting was a common method of treatment as was described by William Osler in his textbook, The Principles and Practice of Medicine, written in 1892.
Historical Perspective
Pneumonia is a disease that has been prevalent for centuries and is a condition that many physicians can claim to have seen and treated in healthcare environments.
One of the earliest confirmed cases of bacterial pneumonia can be traced back to 1880, when Louis Pasteur and George Sternberg first isolated the most common microorganism responsible, Streptococcus pneumoniae. Due to its high mortality rate, pneumonia was often referred to as “captain of the men of death” in the 20th century.[1] In fact, a majority of deaths during the Influenza Pandemic of 1918 were attributed to a fatal bacterial pneumonia following the initial viral infection.[2]
Before the discovery of present-day formidable antibiotics, a common method of treating the disease included bloodletting or the use of leeches, as described by William Osler in his textbook, The Principles and Practice of Medicine, written in 1892.[3] Affected patients would be drained of their blood in hopes of ridding the body of toxins and illnesses. With the discovery of modern medicine, such practices have become sparse with the exception of a few diseases.
References
- ↑ Gennaris A, Collet JF (2013). “The ‘captain of the men of death’, Streptococcus pneumoniae, fights oxidative stress outside the ‘city wall‘“. EMBO Mol Med. 5 (12): 1798–800. doi:10.1002/emmm.201303482. PMC 3914527. PMID 24293314.
- ↑ Morens DM, Taubenberger JK, Fauci AS (2008). “Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness”. J Infect Dis. 198 (7): 962–70. doi:10.1086/591708. PMC 2599911. PMID 18710327.
- ↑ Bryan CS (2019). “New observations support William Osler’s rationale for systemic bloodletting”. Proc (Bayl Univ Med Cent). 32 (3): 372–376. doi:10.1080/08998280.2019.1615331. PMC 6650279 Check
|pmc=value (help). PMID 31384189.
Pathophysiology

Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Philip Marcus, M.D., M.P.H.[2] Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Causative bacteria can be inhaled from the surrounding environment but organisms are also commonly found within the upper respiratory tract of many individuals from where they can be directed towards the alveoli. Once in the bloodstream of the lungs, the immune system triggers a response by mobilizing white blood cells into the affected area. Neutrophils and cytokine help in ridding the body of infectious organisms but also result in systemic symptoms such as fever, chills, and fatigue. If bacteria enters the systemic blood stream, sepsis may ensue and can involve other organs including the brain, kidney, and heart.
Pathophysiology
Bacteria[1]
- Bacteria and fungi also typically enter the lung with inhalation, though they can reach the lung through the bloodstream if other parts of the body are infected. Most commonly, bacteria enter via aspiration, but infection via hematogenous spread may also occur.[2]
- Often, bacteria live in parts of the upper respiratory tract and are constantly being inhaled into the alveoli.
- Once inside the alveoli, bacteria and fungi travel into the spaces between the cells and also between adjacent alveoli through connecting pores.
- This invasion triggers the immune system to respond by sending white blood cells responsible for attacking microorganisms (neutrophils) to the lungs. The neutrophils engulf and kill the offending organisms but also release cytokines which result in a general activation of the immune system.
- Fever, chills, and fatigue are common in CAP. The neutrophils, bacteria, and fluid leaked from surrounding blood vessels fill the alveoli and result in impaired oxygen transportation.
- Bacteria often travel from the lung into the blood stream and can result in serious illness such as septic shock. Inflammation and further damage is further exacerbated by the release of cytokines such as IL-1 and TNF leading to multiorgan failure and septic shock.
- Septic shock results in low blood pressure leading to damage in multiple parts of the body including the brain, kidney, and heart.
References
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Bacterial pneumonia may be due to a variety of underlying causes. The microorganisms responsible are divided into typical and atypical. Typical bacteria often result in a classic pneumonia whereas atypical bacteria lead to a much milder presentation often referred to as “walking pneumonia“. These patients appear near normal but have extensive findings on chest x-ray. Apart from typical and atypical classifications, bacterial pneumonia can be categorized based on demographics by differentiating into neonates (<4 weeks old), toddlers (2 – 4 years), children (4 weeks – 18 years), adults (18 – 65 years), and the elderly (>65 years). Underlying characteristics may also help determine the specific cause. These include alcoholics, those at risk of aspiration, cystic fibrosis, intravenous drug users, and those that are immunocompromised or at risk of nosocomial pneumonia.
Causes
According to Microorganisms
| Typical Pneumonia[1] | Atypical Pneumonia |
|---|---|
| Streptococcus pneumoniae | Legionella |
| Staphylococcus aureus | Mycoplasma pneumoniae |
| Haemophilus influenzae | Chlamydia pneumoniae |
| Listeria monocytogenes | Chlamydia psittaci |
| Group A streptococci | Chlamydia Trachomatis |
| Moraxella catarrhalis | |
| Anaerobes and aerobic gram-negative bacteria |
According to Demographics
| Age Group | Most common organism |
|---|---|
| Neonates (<4 weeks old) [2][3] | Group B streptococci, Escherichia coli, Listeria monocytogenes |
| Toddlers (2 – 4 years) [3] | Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis |
| Children (4 weeks – 18 years) [3] | Streptococcus pneumoniae, Mycoplasma pneumoniae, Haemophilus influenzae |
| Adults (18 – 65 years) [4] | Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Klebsiella, Pseudomonas aeruginosa, Legionella, Mycoplasma pneumoniae, Chlamydia pneumoniae |
| Elderly (>65 years) [5] | Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Legionella, Gram Negative Rods (Escherichia coli, Klebsiella, Enterobacter species, Pseudomonas aeruginosa) |
According to Specific Groups
| Group Description | Most common organism |
|---|---|
| Alcoholics [6][7] | Streptococcus Pneumoniae, Oral anaerobes, Klebsiella Pneumoniae, Acinetobacter |
| Aspiration [6][7] | Oral anaerobes, Pseudomonas aeruginosa, Gram-Negative Rods (Escherichia coli, Klebsiella, Enterobacter species) |
| Cystic fibrosis [6][7] | Pseudomonas Aeruginosa, Burkholderia Cepacia, Staphylococcus Aureus |
| Immunocompromised [6][7] | Streptococcus Pneumoniae, Haemophilus Influenzae |
| Intravenous drug users [6][7] | Staphylococcus Aureus, Oral anaerobes, Streptococcus Pneumoniae |
| Nosocomial (hospital acquired) [8] | Staphylococcus aureus (MRSA), Streptococcus species, Pseudomonas aeruginosa, Gram-Negative Rods (Escherichia coli, Klebsiella, Enterobacter species), Acinetobacter species |
| Postviral [9] | Staphylococcus aureus, Streptococcus Pneumoniae
Less likely to be Haemophilus influenzae |
References
- ↑ “StatPearls”. 2021. PMID 30020693.
- ↑ Webber S, Wilkinson AR, Lindsell D, Hope PL, Dobson SR, Isaacs D (1990). “Neonatal pneumonia”. Arch Dis Child. 65 (2): 207–11. doi:10.1136/adc.65.2.207. PMC 1792235. PMID 2107797.
- ↑ 3.0 3.1 3.2 Nguyen TK, Tran TH, Roberts CL, Graham SM, Marais BJ (2017). “Child pneumonia – focus on the Western Pacific Region”. Paediatr Respir Rev. 21: 102–110. doi:10.1016/j.prrv.2016.07.004. PMC 7106312 Check
|pmc=value (help). PMID 27569107. - ↑ Eshwara VK, Mukhopadhyay C, Rello J (2020). “Community-acquired bacterial pneumonia in adults: An update”. Indian J Med Res. 151 (4): 287–302. doi:10.4103/ijmr.IJMR_1678_19. PMC 7371062 Check
|pmc=value (help). PMID 32461392 Check|pmid=value (help). - ↑ Henig O, Kaye KS (2017). “Bacterial Pneumonia in Older Adults”. Infect Dis Clin North Am. 31 (4): 689–713. doi:10.1016/j.idc.2017.07.015. PMC 7127502 Check
|pmc=value (help). PMID 28916385. - ↑ 6.0 6.1 6.2 6.3 6.4 {{https://www.wikidoc.org/index.php/Pneumonia_risk_factors}}
- ↑ 7.0 7.1 7.2 7.3 7.4 {{https://academic.oup.com/cid/article/44/Supplement_2/S27/372079}}
- ↑ “StatPearls”. 2021. PMID 30571062.
- ↑ Prasso JE, Deng JC (2017). “Postviral Complications: Bacterial Pneumonia”. Clin Chest Med. 38 (1): 127–138. doi:10.1016/j.ccm.2016.11.006. PMC 5324726. PMID 28159155.
Differentiating Bacterial pneumonia from other Diseases
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Symptoms related to pulmonary diseases may overlap, and so, it is important to differentiate bacterial causes from other diseases. This can be done with the assistance of laboratory examinations such as chest x-ray findings, throat cultures, and sensitivity bacterial cultures. Some pulmonary diseases that must be differentiated include bronchitis, bronchiolitis obliterans, empyema, lung abscess, and pulmonary carcinomas. Other diseases to be ruled out include bacterial endocarditis, especially in patients with an underlying history of intravenous drug abuse, GERD, and sinusitis.
Differentiating Bacterial Pneumonia from other Diseases
| Disease | Common Organisms |
|---|---|
| Typical Bacterial | S. pneumoniae, H. influenzae, S. aureus, Klebsiella pneumoniae, anaerobes, group A streptococci, Moraxella catarrhalis |
| Atypical Bacterial | Mycoplasma pneumoniae, Legionella spp, Chlamydophila pneumoniae, and C. psittaci |
| Viral | Influenza virus, Parainfluenza virus, Adenovirus, Rhinovirus, RSV, SARS, MERS-CoV |
| Fungi | Cryptococcus spp, Pneumocystis jirovecii, Histoplasma capsulatum, Coccidioides spp, Aspergillus spp |
| Parasite |
| Disease | Findings |
|---|---|
| Acute bronchitis | No infiltrates seen on the chest X-ray |
| Asthma | Past medical history, no infiltrates seen on chest X-ray |
| Bronchiolitis obliterans | Should be suspected in patients with pneumonia who do not respond to antibiotics treatment |
| Congestive heart failure | Bilateral pulmonary edema, shortness of breath |
| COPD | Past medical history, no infiltrates on chest X-ray, fever is uncommon |
| Empyema | CXR showing features of pleural effusion, inflammatory markers on thoracocentesis |
| Endocarditis | Finding of septic pulmonary emboli |
| Gastroesophageal reflux disease (GERD) | Normal chest X-ray, symptoms are worse during night and associated with meals |
| Lung abscess | Chest X-ray shows signs of lung abscess |
| Lung cancer | Weight loss and clear sputum. CT scan and biopsy are helpful in ruling out malignancy |
| Pertussis | Productive cough for weeks, nasopharyngeal aspirate aids in diagnosis |
| Pulmonary embolus | A high degree of suspicion should be kept for pulmonary embolus. Chest X-ray may be normal |
| Sinusitis | Sinus tenderness, post nasal drip |
| Vasculitis | Systemic manifestations of collagen vascular disease may be seen |
References
- ↑ Schiele F, Muller J, Colinet E, Siest G, Arzoglou P, Brettschneider H; et al. (1992). “Interlaboratory study of the IFCC method for alanine aminotransferase performed with use of a partly purified reference material”. Clin Chem. 38 (12): 2365–71. PMID 1458569.
- ↑ Castro-Guardiola A, Armengou-Arxé A, Viejo-Rodríguez A, Peñarroja-Matutano G, Garcia-Bragado F (2000). “Differential diagnosis between community-acquired pneumonia and non-pneumonia diseases of the chest in the emergency ward”. Eur J Intern Med. 11 (6): 334–339. PMID 11113658.
- ↑ Ahnsjö, Sven (1935). “Contribution to the Differential Diagnosis of Pneumonia in Childhood”. Acta Paediatrica. 17 (3): 439–446. doi:10.1111/j.1651-2227.1935.tb07697.x. ISSN 0803-5253.
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
- Pneumonia is a condition seen in a vast majority of regions, but pneumonia related deaths have been disproportionately higher in low and middle income nations, including the sub-Saharan African and South Asian regions.[1]
- Pneumonia case rates are primarily affected by factors relating to seasonal variations. Studies show that a majority of Streptococcus pneumoniae cases were most prevalent during the winter, whereas far fewer cases presented in the summertime in comparison. Specifications regarding geography are of considerable importance in regards to fungal pneumonia.[2]
Incidence
- Approximately 5 million people are affected every year in the United States alone, with outpatients making up the majority at 80% but having a low mortality rate of 1%. Up to half of the patients that are admitted into hospitals succumb to the disease.[3]
- Worldwide, the incidence of community acquired pneumonia averages 1.5-14 cases per every 1000 individuals.[2]
- The incidence in the United States is approximately 25 cases per 10,000 adults.[2]
- The CDC estimates that Streptococcus pneumoniae alone is responsible for nearly 150,000 hospitalizations in the United States annually.[4]
References
- ↑ Roomaney RA, Pillay-van Wyk V, Awotiwon OF, Dhansay A, Groenewald P, Joubert JD; et al. (2016). “Epidemiology of lower respiratory infection and pneumonia in South Africa (1997-2015): a systematic review protocol”. BMJ Open. 6 (9): e012154. doi:10.1136/bmjopen-2016-012154. PMC 5030548. PMID 27633638.
- ↑ 2.0 2.1 2.2 “StatPearls”. 2021. PMID 28613500.
- ↑ “StatPearls”. 2021. PMID 30020693.
- ↑ “CDC Pneumococcal Disease Clinical Features”.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Bacterial pneumonia can affect individuals of any age, gender, or race and has minimal significance in relation to family history. Individuals with underlying immunoglobulin defects have a significantly higher likelihood of infection. Bacterial pneumonia tends to affect men more often than women, and is more common in African Americans compared to Caucasians. Socioeconomic status is an important contributing factors and may explain the increased prevalence rate in low to middle-income nations. Pneumonia may also be affected by the use of medications such as proton pump inhibitors and ACE inhibitors. Immunocompromised patients requiring in-hospital treatment may develop nosocomial pneumonia but this can also present in seemingly healthy patients with prolonged durations of stay. A majority of nosocomial pneumonia will developed within 48 hours but some may present later on. The most common pathogens causing nosocomial pneumonia include Gram-positive cocci (e.g, Staphylococcus aureus, which includes methicillin-resistant S. aureus, and Streptococcus species) and Aerobic gram-negative bacilli (e.g. Pseudomonas Aeruginosa, Escherichia Coli, Klebsiella Pneumoniae, Enterobacter species, Acinetobacter species).
Risk Factors
Common risk factors in the development of bacterial pneumonia include:
- Age; Infants and geriatric patients greater than 65 years[1]
- Comorbidities[2]
- Underlying Genetic conditions[3]
- Smoking[4]
- Excessive alcohol intake[1]
- Post viral complication[5] (often after an Influenza infection)
- Immunosuppresion (eg, HIV, use of corticosteroids that may be iatrogenic)[1]
- Low socioeconomic status [6]
- Males[7]
- African Americans[7]
Pneumonia in relation to other Drugs/ Other medications used:
- Atypical antipsychotics have been shown to increase the risk of pneumonia, especially in elderly individuals.[8]
- Use of Acid Suppressing drugs (H2 blockers, proton pump inhibitors, and other antacids) may increase the risk of pneumonia.[9]
- ACE inhibitors may be helpful in reducing the risk of pneumonia.[10]
Risk Factors and specific bacterial microorganisms leading to Pneumonia:
| Underlying Condition[11][12] | Most Common Bacterial Microorganisms |
|---|---|
| Alcohol Abuse | Streptococcus Pneumoniae, oral anaerobes, Klebsiella Pneumoniae, Acinetobacter |
| Aspiration | Oral anaerobes, Gram-negative enteric bacteria |
| COPD | Haemophilus Influenzae, Pseudomonas Aeruginosa, Legionella, Streptococcus Pneumoniae, Moraxella Catarrhalis |
| Endotracheal Obstruction | Streptococcus Pneumoniae, oral flora anaerobes, Haemophilus Influenzae, Staphylococcus Aureus |
| Lung Abscess | Community-acquired MRSA, oral anaerobes, Atypical Mycobacteria |
| HIV | Streptococcus Pneumoniae, Haemophilus Influenzae |
| IV Drug Abuse | Staphylococcus Aureus, oral anaerobes, Streptococcus Pneumoniae |
| Smoking | Haemophilus Influenzae, Pseudomonas Aeruginosa, Legionella, Streptococcus Pneumoniae, Moraxella Catarrhalis |
| Structural Lung Diseases | Pseudomonas Aeruginosa, Burkholderia Cepacia, Staphylococcus Aureus |
| Avian Related | Chlamydia psittaci |
Nosocomial Pneumonia:
While in the hospital, especially after surgical procedures when immunity may be affected, patients are at risk of acquiring infections, especially with certain strains of bacteria. Furthermore, patients with pre-existing comorbidities or risk factors and have a prolonged duration of stay at the hospital predisposing them to increased susceptibility. A majority of cases of nosocomial pneumonia occur after 48 hours or more. The most common pathogens causing pneumonia include:[13]
- Gram-positive cocci (e.g, Staphylococcus aureus, which includes methicillin-resistant S. aureus, and Streptococcus species)
- Aerobic gram-negative bacilli (e.g. Pseudomonas Aeruginosa, Escherichia Coli, Klebsiella Pneumoniae, Enterobacter species, Acinetobacter species)
References
- ↑ 1.0 1.1 1.2 “StatPearls”. 2021. PMID 28613500.
- ↑ Alshahwan SI, Alsowailmi G, Alsahli A, Alotaibi A, Alshaikh M, Almajed M; et al. (2019). “The prevalence of complications of pneumonia among adults admitted to a tertiary care center in Riyadh from 2010-2017”. Ann Saudi Med. 39 (1): 29–36. doi:10.5144/0256-4947.2019.29. PMC 6464674. PMID 30712048.
- ↑ Schussler E, Beasley MB, Maglione PJ (2016). “Lung Disease in Primary Antibody Deficiencies”. J Allergy Clin Immunol Pract. 4 (6): 1039–1052. doi:10.1016/j.jaip.2016.08.005. PMC 5129846. PMID 27836055.
- ↑ Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM (2019). “Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis”. PLoS One. 14 (7): e0220204. doi:10.1371/journal.pone.0220204. PMC 6638981 Check
|pmc=value (help). PMID 31318967. - ↑ Prasso JE, Deng JC (2017). “Postviral Complications: Bacterial Pneumonia”. Clin Chest Med. 38 (1): 127–138. doi:10.1016/j.ccm.2016.11.006. PMC 5324726. PMID 28159155.
- ↑ Roomaney RA, Pillay-van Wyk V, Awotiwon OF, Dhansay A, Groenewald P, Joubert JD; et al. (2016). “Epidemiology of lower respiratory infection and pneumonia in South Africa (1997-2015): a systematic review protocol”. BMJ Open. 6 (9): e012154. doi:10.1136/bmjopen-2016-012154. PMC 5030548. PMID 27633638.
- ↑ 7.0 7.1 “StatPearls”. 2021. PMID 30020693.
- ↑ Knol W, van Marum RJ, Jansen PA, Souverein PC, Schobben AF, Egberts AC (2008). “Antipsychotic drug use and risk of pneumonia in elderly people”. J Am Geriatr Soc. 56 (4): 661–6. doi:10.1111/j.1532-5415.2007.01625.x. PMID 18266664.
- ↑ Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004). “Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs”. JAMA. 292 (16): 1955–60. doi:10.1001/jama.292.16.1955. PMID 15507580.
- ↑ Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J (2012). “Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis”. BMJ. 345: e4260. doi:10.1136/bmj.e4260. PMC 3394697. PMID 22786934. Review in: Ann Intern Med. 2012 Nov 20;157(10):JC5-2
- ↑ {{https://academic.oup.com/cid/article/44/Supplement_2/S27/372079}}
- ↑ {{https://www.wikidoc.org/index.php/Pneumonia_risk_factors}}
- ↑ “StatPearls”. 2021. PMID 30571062.
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
Bacterial pneumonia is often transmitted via oral secretions and undergoes a variety of stages including congestion, hepatization and resolution. Symptoms may vary amongst individuals but commonly include abrupt fever, chills, rigors, and cough. Infectious organisms are commonly transmitted via oral secretions containing droplets and the incubation period is generally short and ranges from 1-3 days. Germs can also be transferred by touching unclean surfaces with hands that may later come in contact with the eyes, nostrils, or mouth allowing bacteria to enter the body. There are a multitude of pulmonary and extra-pulmonary complications that contribute to determining the outcome of recovery. Common complications include acute respiratory distress, pleural effusion, sepsis and shock. Prognosis varies according to age and underlying conditions such as bronchiectasis, abscesses, and neoplasms. The CURB-65 scale takes into account confusion, BUN, respiratory rate, blood pressure, and age. A score of 3 or more requires a prolonged hospital duration and has a higher risk of mortality. This criteria has proven to be a useful tool in predicting the outcome of disease.
Natural History
Route of Transmission
- Contamination is via oral secretions containing droplets; this commonly occurs when coughing or sneezing.[1]
- Germs can also be transferred by touching unclean surfaces with hands that may later come in contact with the eyes, nostrils, or mouth allowing bacteria to enter the body.
Incubation period
- The incubation period is generally short and ranges from 1-3 days.[2] This does not however determine the period an individual may experience symptoms for, which may be prolonged due to the development of complications.
Presenting Symptoms
- Common symptoms:[2] abrupt fever, chills, rigors, cough (often productive). If present, the colour of any phlegm may help determine the underlying pathogen but must still be confirmed to treat with the correct antibiotics. Some examples of sputum specifications include:[3]
- Currant Jelly sputum: Klebsiella
- Rust coloured sputum: Streptococcus pneumoniae
- Green sputum: Hemophilus, Pseudomonas
- Foul smelling/ bad-tasting sputum: Anaerobes
- Other symptoms:[2] pleuritic chest pain, dyspnea, tachypnea, myalgias, generalized weakness and fatigue
Stages
Bacterial Pneumonia progresses through a variety of Stages that include:[4]
- Congestion: The first stage stage shows a lobe that consists of many neutrophils, some macrophages and serous exudates in the alveoli. Presents on days 1-2 of the infection.
- Red hepatization: During this period, the lung lobe undergoes consolidation and appears firm resembling the appearance of that of the liver. There is an abundance of neutrophils, macrophages as well as serous exudate. Presents on days 3-4 of the infection.
- Gray hepatization: The lobe continues to appear liver like but had changed rather than red, no appears slightly gray in colour. Presents on days 5-7 of the infection.
- Resolution:The final stage of pneumonia is aided by productive cough and/or increased lymphatic drainage in an attempt to “drain” the bacteria and help the lung lobe resolve. Presents around day 8 of the infection.
Complications
- Common Complications:[3]
- Acute respiratory distress
- Pleural effusion (unilateral or bilateral)
- Heart Failure due to Pneumonia
- Sepsis
- Septic shock
- Other Complications:[4]
- Bronchiectasis
- Pleurisy
- Empyema
- Arrhythmias
- Acute coronary syndrome
- Endocarditis
- Encephalitis
- Meningitis
Prognosis
- There is a relatively good prognosis in patients that are younger with fewer comorbidities and considered generally healthy. As a patients age increases, so does the likelihood of an unfavourable outcome. Antibiotic resistance poses difficulty in adequately treating patients and may affect failure rates.[4]
- The CURB 65 Score[5] is used as a standard score to predict mortality rates following pneumonia infections. A score of 0 -1 is considered low risk and has a minimal risk of death, 2 is generally an intermediate risk requiring a short inpatient hospital stay with an increased risk of 30 – day mortality. A score of 3 or more requires a prolonged hospital duration and has a higher risk of mortality.
Each of the following categories is 1 point:
- Confusion (new onset)
- Blood urea nitrogen >7 mmol/L
- Respiratory rate ≥ 30 breaths/ minute
- Systolic blood pressure < 90 mm Hg or Diastolic blood pressure ≤ 60 mm Hg
- Age ≥ 65 years
If patients are non-responsive to antibiotics, a non-resolving pneumonia may develop after a period of approximately 72 hours[6]. In such cases, the mortality increases 5 fold. This subtype of non-resolving pneumonia may appear in two conditions:
- progressively resolving pneumonia followed by a rapid clinical deterioration or
- persistent pneumonia that has not displayed clinical stability
Some underlying conditions may prove to exacerbate the development of non-resolving pneumonia. These include (BAD OMEN):
Bronchiolitis obliterans, Bronchiectasis, Influenza B
Age > 60, Aspiration, Abscess, Atypical pathogens eg, Legionella, Mycoplasma, Chlamydia
Drug resistant pneumonia
Opportunistic pathogens
Misdiagnosis (fungal infections, sarcoidosis, Tuberculosis)
Nosocomial pneumonia, Neoplasm
References
- ↑ https://www.nhs.uk/common-health-questions/infections/is-pneumonia-contagious/. Missing or empty
|title=(help) - ↑ 2.0 2.1 2.2 “CDC Pneumococcal Disease Clinical Features”.
- ↑ 3.0 3.1 Alshahwan SI, Alsowailmi G, Alsahli A, Alotaibi A, Alshaikh M, Almajed M; et al. (2019). “The prevalence of complications of pneumonia among adults admitted to a tertiary care center in Riyadh from 2010-2017”. Ann Saudi Med. 39 (1): 29–36. doi:10.5144/0256-4947.2019.29. PMC 6464674. PMID 30712048.
- ↑ 4.0 4.1 4.2 “StatPearls”. 2021. PMID 30020693.
- ↑ Nguyen Y, Corre F, Honsel V, Curac S, Zarrouk V, Fantin B; et al. (2020). “Applicability of the CURB-65 pneumonia severity score for outpatient treatment of COVID-19”. J Infect. 81 (3): e96–e98. doi:10.1016/j.jinf.2020.05.049. PMC 7255987 Check
|pmc=value (help). PMID 32474039 Check|pmid=value (help). - ↑ Grief SN, Loza JK (2018). “Guidelines for the Evaluation and Treatment of Pneumonia”. Prim Care. 45 (3): 485–503. doi:10.1016/j.pop.2018.04.001. PMC 7112285 Check
|pmc=value (help). PMID 30115336.
Diagnosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Chest X Ray | CT | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
